GS-4774 is a heat-inactivated, yeast-based, T-cell vaccine designed to elicit hepatitis B virus (HBV)-specific T-cell responses. We evaluated the safety, tolerability and efficacy of GS-4774 in patients with chronic HBV infection.

Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B / Lok, A.S., Pan, C.Q., Han, S.H.B., Trinh, H.N., Fessel, W.J., Rodell, T., Massetto, B., Lin, L., Gaggar, A., Subramanian, G.M., Mchutchison, J.G., Ferrari, C., Lee, H., Gordon, S.C., Gane, E.J.. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - 65:3(2016), pp. 509-16-516. [10.1016/j.jhep.2016.05.016]

Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B

FERRARI, Carlo;
2016-01-01

Abstract

GS-4774 is a heat-inactivated, yeast-based, T-cell vaccine designed to elicit hepatitis B virus (HBV)-specific T-cell responses. We evaluated the safety, tolerability and efficacy of GS-4774 in patients with chronic HBV infection.
2016
Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B / Lok, A.S., Pan, C.Q., Han, S.H.B., Trinh, H.N., Fessel, W.J., Rodell, T., Massetto, B., Lin, L., Gaggar, A., Subramanian, G.M., Mchutchison, J.G., Ferrari, C., Lee, H., Gordon, S.C., Gane, E.J.. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - 65:3(2016), pp. 509-16-516. [10.1016/j.jhep.2016.05.016]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2814132
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 178
  • ???jsp.display-item.citation.isi??? 156
social impact